Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 3/20 | 0.58 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.58 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.58 |
| ▸ | HTR1A | P08908 | 2/20 | 0.58 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.58 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.58 |
| ▸ | DRD1 | P21728 | 2/20 | 0.58 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.58 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.58 |
| ▸ | DRD3 | P35462 | 2/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.58 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.58 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.58 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.58 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.58 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.58 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.58 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.58 |
| ▸ | DRD2 | P14416 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28403562 | 1.00 | TBXA2R (0.58) | TBXA2RADRA1ASLC6A3HTR1AADRA2A | |
| SCHEMBL28488243 | 0.93 | GAA (0.53) | TBXA2RADRA1ASLC6A3HTR1AADRA2A | |
| Hydrochloric Acid SCHEMBL28497871 | 0.92 | GAA (0.52) | TBXA2RADRA1ASLC6A3HTR1AADRA2A | |
| SCHEMBL29259269 | 0.90 | GAA (0.48) | TBXA2RADRA1ASLC6A3HTR1AADRA2A | |
| SCHEMBL28488906 | 0.88 | GAA (0.48) | TBXA2RADRA1ASLC6A3HTR1AADRA2A | |
| SCHEMBL19687545 | 0.84 | TBXA2R (0.66) | TBXA2RADRA1ASLC6A3HTR1AADRA2A | |
| SCHEMBL28356025 | 0.84 | CYP2C9 (0.50) | TBXA2RADRA1ASLC6A3HTR1AADRA2A | |
| SCHEMBL28342075 | 0.83 | KDM4E (0.55) | TBXA2RADRA1ASLC6A3HTR1AADRA2A | |
| SCHEMBL11130109 | 0.83 | TBXA2R (0.42) | TBXA2RADRA1ASLC6A3HTR1AADRA2A | |
| SCHEMBL14987090 | 0.80 | TSHR (0.74) | TBXA2RADRA1ASLC6A3ABCB11ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6784297-B2 | CONDENSING PHTHALIC ANHYDRIDE AND ETHANOLAMINE, COUPLING WITH ETHYL 4-CHLORACETOACETATE/O-CHLOROBENZALDEHYDE, CONDENSING (CYCLIZATION) WITH METHYL AMINOCROTONATE, PURIFYING, HYDROLYZING, SALT FORMING; COMMERCIALLY VIABLE; EFFICIENCY | KOPRAN LIMITED (IN) | 2004-08-31 | — | — | US | claimed |
| US-20040044218-A1 | Reacting phthalic anhydride with ethanolamine | KOPRAN LIMITED (IN) | 2004-03-04 | — | — | US | claimed |
| US-6680334-B2 | Crystalline material | PFIZER INC | 2004-01-20 | — | — | US | claimed |
| US-20030119883-A1 | Crystalline material | PFIZER INC. | 2003-06-26 | — | — | US | claimed |
| EP-1287826-A1 | A crystalline form of the free base of Amlodipine | Pfizer Limited (GB) | 2003-03-05 | — | — | EP | claimed |
| US-6784297-B2 | CONDENSING PHTHALIC ANHYDRIDE AND ETHANOLAMINE, COUPLING WITH ETHYL 4-CHLORACETOACETATE/O-CHLOROBENZALDEHYDE, CONDENSING (CYCLIZATION) WITH METHYL AMINOCROTONATE, PURIFYING, HYDROLYZING, SALT FORMING; COMMERCIALLY VIABLE; EFFICIENCY | KOPRAN LIMITED (IN) | 2004-08-31 | — | — | US | disclosed |
| US-6784297-B2 | CONDENSING PHTHALIC ANHYDRIDE AND ETHANOLAMINE, COUPLING WITH ETHYL 4-CHLORACETOACETATE/O-CHLOROBENZALDEHYDE, CONDENSING (CYCLIZATION) WITH METHYL AMINOCROTONATE, PURIFYING, HYDROLYZING, SALT FORMING; COMMERCIALLY VIABLE; EFFICIENCY | KOPRAN LIMITED (IN) | 2004-08-31 | — | — | US | disclosed |
| WO-2004033429-A1 | CRYSTALLINE 2- `(2-AMINOETHOXY) METHYL!-4-(2-CHLOROPHENYL) -3-ETHOXYCARBONYL-5-METHOXYCARBONYL-6- METHYL-1, 4-DIHYDROPYRIDINE MALEATE SALT (AMPLODIPINE) | DR. REDDY'S LABORATORIES LIMITED (IN) | 2004-04-22 | — | — | WO | disclosed |
| US-20040044218-A1 | Reacting phthalic anhydride with ethanolamine | KOPRAN LIMITED (IN) | 2004-03-04 | — | — | US | disclosed |
| US-20040044218-A1 | Reacting phthalic anhydride with ethanolamine | KOPRAN LIMITED (IN) | 2004-03-04 | — | — | US | disclosed |
| US-6680334-B2 | Crystalline material | PFIZER INC | 2004-01-20 | — | — | US | disclosed |
| US-6596874-B1 | Salt formation by reaction using benzenesulfonic acid | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2003-07-22 | — | — | US | disclosed |
| US-20030119883-A1 | Crystalline material | PFIZER INC. | 2003-06-26 | — | — | US | disclosed |
| EP-1287826-A1 | A crystalline form of the free base of Amlodipine | Pfizer Limited (GB) | 2003-03-05 | — | — | EP | disclosed |
| US-4515799-A | Dihydropyridine anti-ischaemic and antihypertensive agents | PFIZER INC. (US) | 1985-05-07 | — | — | US | disclosed |
| EP-0100189-A2 | Dihydropyridine anti-ischaemic and antihypertensive agents | Pfizer Limited (GB) | 1984-02-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044218-A1 | Reacting phthalic anhydride with ethanolamine | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CA2, H1-4 | TBXA2R 3932/4885ADRA1A 2821/4885SLC6A3 3655/4885 |
| US-20030119883-A1 | Crystalline material | REN, CACNA1C, CACNA1B | TBXA2R 1135/4885ADRA1A 837/4885SLC6A3 2303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.